304 related articles for article (PubMed ID: 32142667)
21. ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.
Wrobel K; Zhao YC; Kulkoyluoglu E; Chen KL; Hieronymi K; Holloway J; Li S; Ray T; Ray PS; Landesman Y; Lipka AE; Smith RL; Madak-Erdogan Z
Mol Endocrinol; 2016 Oct; 30(10):1029-1045. PubMed ID: 27533791
[TBL] [Abstract][Full Text] [Related]
22. Merlin cooperates with neurofibromin and Spred1 to suppress the Ras-Erk pathway.
Cui Y; Ma L; Schacke S; Yin JC; Hsueh YP; Jin H; Morrison H
Hum Mol Genet; 2021 Feb; 29(23):3793-3806. PubMed ID: 33331896
[TBL] [Abstract][Full Text] [Related]
23. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
[TBL] [Abstract][Full Text] [Related]
24. HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells.
Ohe K; Miyajima S; Abe I; Tanaka T; Hamaguchi Y; Harada Y; Horita Y; Beppu Y; Ito F; Yamasaki T; Terai H; Mori M; Murata Y; Tanabe M; Ashida K; Kobayashi K; Enjoji M; Yanase T; Harada N; Utsumi T; Mayeda A
J Steroid Biochem Mol Biol; 2018 Sep; 182():21-26. PubMed ID: 29678492
[TBL] [Abstract][Full Text] [Related]
25. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.
Shapira S; Barkan B; Friedman E; Kloog Y; Stein R
Cell Death Differ; 2007 May; 14(5):895-906. PubMed ID: 17096025
[TBL] [Abstract][Full Text] [Related]
26. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
27. Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.
Kim BJ; Zheng ZY; Lei JT; Holt MV; Chen A; Peng J; Fandino D; Singh P; Kennedy H; Dou Y; Chica-Parrado MDR; Bikorimana E; Ye D; Wang Y; Hanker AB; Mohamed N; Hilsenbeck SG; Lim B; Asirvatham JR; Sreekumar A; Zhang B; Miles G; Anurag M; Ellis MJ; Chang EC
Cancer Res Commun; 2023 Jul; 3(7):1366-1377. PubMed ID: 37501682
[TBL] [Abstract][Full Text] [Related]
28. Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Nagasawa J; Govek S; Kahraman M; Lai A; Bonnefous C; Douglas K; Sensintaffar J; Lu N; Lee K; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Joseph JD; Darimont B; Brigham D; Maheu K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2018 Sep; 61(17):7917-7928. PubMed ID: 30086626
[TBL] [Abstract][Full Text] [Related]
29. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
30. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
Yang Z; Barnes CJ; Kumar R
Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
[TBL] [Abstract][Full Text] [Related]
31. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor.
Cichowski K; Santiago S; Jardim M; Johnson BW; Jacks T
Genes Dev; 2003 Feb; 17(4):449-54. PubMed ID: 12600938
[TBL] [Abstract][Full Text] [Related]
32. Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.
Xin L; Min J; Hu H; Li Y; Du C; Xie B; Cheng Y; Deng X; Deng X; Shen K; Huang J; Chen CC; Guo RT; Dong C; Zhou HB
Eur J Med Chem; 2023 May; 253():115328. PubMed ID: 37037140
[TBL] [Abstract][Full Text] [Related]
33. Annonacin induces cell cycle-dependent growth arrest and apoptosis in estrogen receptor-α-related pathways in MCF-7 cells.
Ko YM; Wu TY; Wu YC; Chang FR; Guh JY; Chuang LY
J Ethnopharmacol; 2011 Oct; 137(3):1283-90. PubMed ID: 21840388
[TBL] [Abstract][Full Text] [Related]
34. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
35. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B
PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927
[TBL] [Abstract][Full Text] [Related]
36. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
37. Neurofibromatosis 1: closing the GAP between mice and men.
Dasgupta B; Gutmann DH
Curr Opin Genet Dev; 2003 Feb; 13(1):20-7. PubMed ID: 12573431
[TBL] [Abstract][Full Text] [Related]
38. ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer.
Zhang J; Zhou C; Jiang H; Liang L; Shi W; Zhang Q; Sun P; Xiang R; Wang Y; Yang S
Cell Death Dis; 2017 Apr; 8(4):e2732. PubMed ID: 28383555
[TBL] [Abstract][Full Text] [Related]
39. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
[TBL] [Abstract][Full Text] [Related]
40. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
